FI970071L - Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuumorihyljintäantigeeniä - Google Patents

Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuumorihyljintäantigeeniä Download PDF

Info

Publication number
FI970071L
FI970071L FI970071A FI970071A FI970071L FI 970071 L FI970071 L FI 970071L FI 970071 A FI970071 A FI 970071A FI 970071 A FI970071 A FI 970071A FI 970071 L FI970071 L FI 970071L
Authority
FI
Finland
Prior art keywords
hla
nucleic acid
acid sequence
sequence encoding
isolated nucleic
Prior art date
Application number
FI970071A
Other languages
English (en)
Swedish (sv)
Other versions
FI970071A0 (fi
FI970071A7 (fi
Inventor
Vincent Brichard
Pel Aline Van
Pierre Coulie
Thierry Boon-Falleur
Plaen Etienne De
Catia Traversari
Thomas Wolfel
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of FI970071A0 publication Critical patent/FI970071A0/fi
Publication of FI970071L publication Critical patent/FI970071L/fi
Publication of FI970071A7 publication Critical patent/FI970071A7/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FI970071A 1994-07-08 1995-06-27 Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuum orihyljintäantigeeniä FI970071A7 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27235194A 1994-07-08 1994-07-08
US08/370,319 US5856091A (en) 1993-03-18 1995-01-10 Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
PCT/US1995/008153 WO1996001557A1 (en) 1994-07-08 1995-06-27 Isolated nucleic acid sequence coding for a tumor rejection antigen presented by hla-a2

Publications (3)

Publication Number Publication Date
FI970071A0 FI970071A0 (fi) 1997-01-07
FI970071L true FI970071L (fi) 1997-01-07
FI970071A7 FI970071A7 (fi) 1997-01-07

Family

ID=26955454

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970071A FI970071A7 (fi) 1994-07-08 1995-06-27 Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuum orihyljintäantigeeniä

Country Status (10)

Country Link
US (2) US5856091A (fi)
EP (1) EP0772626A4 (fi)
JP (1) JPH10503928A (fi)
CN (1) CN1152251A (fi)
AU (1) AU696738B2 (fi)
CA (1) CA2194451A1 (fi)
FI (1) FI970071A7 (fi)
NO (1) NO970030D0 (fi)
NZ (1) NZ289616A (fi)
WO (1) WO1996001557A1 (fi)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US6013481A (en) * 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
EP0756604A1 (en) * 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigens
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
US5674749A (en) * 1996-03-26 1997-10-07 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor melan-A, and uses thereof
AU727028B2 (en) * 1996-06-25 2000-11-30 Ludwig Institute For Cancer Research Brain glycogen phosphorylase cancer antigen
US6080399A (en) * 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
US8088379B2 (en) * 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
WO2014012051A1 (en) * 2012-07-12 2014-01-16 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
CN113913505A (zh) * 2014-07-15 2022-01-11 亿明达股份有限公司 生物化学激活的电子装置
US10987045B2 (en) 2015-09-14 2021-04-27 Biosense Webster (Israel) Ltd. Basket catheter with individual spine control

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297893A (en) 1963-09-19 1967-01-10 Litz Co Brush mechanisms
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5620886A (en) 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods

Also Published As

Publication number Publication date
CN1152251A (zh) 1997-06-18
CA2194451A1 (en) 1996-01-25
WO1996001557A1 (en) 1996-01-25
AU2951795A (en) 1996-02-09
AU696738B2 (en) 1998-09-17
US6201111B1 (en) 2001-03-13
FI970071A0 (fi) 1997-01-07
NO970030L (no) 1997-01-06
NO970030D0 (no) 1997-01-06
EP0772626A4 (en) 1997-09-10
FI970071A7 (fi) 1997-01-07
NZ289616A (en) 1997-12-19
JPH10503928A (ja) 1998-04-14
EP0772626A1 (en) 1997-05-14
US5856091A (en) 1999-01-05

Similar Documents

Publication Publication Date Title
FI914908A0 (fi) Ny monoklonal antikropp med ny antigen relaterad till humana tumoerer.
FI922071A0 (fi) Slaet, genom munnen till struphuvudet och matstrupen ledande och riktad anordning.
FI913891A7 (fi) Uusi monoklonaalinen vasta-aine uutta antigeenia vastaan, joka liittyy ihmisen kasvaimiin
FI884645A7 (fi) Applikator foer venmanschett, patron och manschett.
DE3883899D1 (de) Geänderte antikörper.
DE3854177D1 (de) Planarspule.
FI884352L (fi) Stabila bionedbrytbara mjukgoeringsmedel foer tyger, vilka innehaoller lineaera alkoxilerade alkoholer.
FI864943A0 (fi) Abonnentenhet foer ett traodloest, digitaliskt telefonsystem.
DE69018801D1 (de) Chimärischer anti-cae-antikörper.
FI901256A0 (fi) Formulationer som administreras genom slemhinna.
DK296189A (da) Nucleinsyresekvenser, som koder for peptidsekvenser af carcinoembryonisk antigen-familien
DE69023277D1 (de) Orthodontische Schraubenfeder.
FI870005A0 (fi) Laogviskoesa hoegmolekulaera genom filtrering steriliserbara hyaluronsyror.
FI862761A0 (fi) Klonad antigen.
FI862037L (fi) Fasta, fytoaktiva blandningar, anvaendningfoerfarande och framstaellningsfoerfarande.
FI970071L (fi) Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuumorihyljintäantigeeniä
FI906305L (fi) Genom industning erhaollen laogfettsost.
DK163062C (da) Antigen, immunogen, proteinholdig vaccine imod coccidiose
FI861691A7 (fi) Uusi kasvaimiin liittyvä antigeeni.
DK169987D0 (da) Human tumor-associated antigen, ca-ou1
NO965087D0 (no) Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav
FI902803A7 (fi) DNA-sekvenssi, joka koodaa a-amylaasi-pullulanaasientsyymiä
DE68909203D1 (de) Gewickelte Feder.
NO873488L (no) Monoklonale antistoffer.
FI864397L (fi) Magasin foer stapling av plaotdelar, saerskilt foer framstaellning av daosor.